1st Mar 2018
Alliance Pharma plc
(AIM: APH), the specialty pharmaceutical group, announces the appointment of a new Chairman, the succession of the Deputy CEO to CEO and the current CEO’s transition to a non-executive role.
Peter Butterfield, currently Deputy CEO, will take over from John Dawson as CEO on 1 May 2018. John Dawson, who founded Alliance in 1996, will remain on the Board as a Non-executive Director.
Peter Butterfield, Alliance’s Deputy CEO, commented:
“I am delighted to be taking on the leadership of Alliance as it continues to grow. It has been a real pleasure working alongside John and I’m very pleased that he has decided to continue his involvement with the Company as a Non-executive Director.”
Appointment of Chairman
Alliance also announces that, following a search process involving internal and external candidates, as of today David Cook, a Non-Executive Director of the Company for almost four years, will take over as Non-executive Chairman from Andrew Smith, who will today step down from Alliance’s Board. David Cook is a chartered accountant who worked in professional practice for 13 years with PwC, following which he has worked for 14 years in the pharmaceutical industry, including roles at EUSA Pharma Inc, Jazz Pharmaceuticals Ltd and Biotie Therapies Corporation. He is currently Chief Financial Officer of Ellipses Pharma Limited.
Commenting on the Board changes, John Dawson, Alliance’s CEO
, said: “It has been enormously gratifying to have developed Alliance over more than twenty years and to have grown the Company into a successful international business. I look forward to continuing to contribute to Alliance as a Non-executive Director.
“Peter Butterfield and I have worked closely together since he joined Alliance following our acquisition of Cambridge Laboratories eight years ago. His career path has been impressive and his capabilities give the Board the utmost confidence that, as CEO, Peter will be highly effective in driving the Company forward.
“David Cook has been an invaluable Board member over the past four years and we are delighted that he has agreed to chair the Board as the Company continues on its growth trajectory. Additionally, on behalf of the Board, I would like to thank Andrew Smith for his sound contribution to the Board over the past 11 years and in particular for his chairmanship since 2014. We wish him well for the future.”
For further information:
Alliance Pharma plc
+ 44 (0) 1249 466966
John Dawson, Chief Executive Officer
Peter Butterfield, Deputy Chief Executive Officer
Andrew Franklin, Chief Financial Officer
+ 44 (0) 20 7466 5000
Mark Court / Sophie Wills / Gemma Mostyn-Owen
Numis Securities Limited
+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock
Investec Bank plc
+44 (0) 20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Rob Baker
Notes to editors
About Alliance Pharma
Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.